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Use of a postoperative insulin protocol decreases
wound infection in diabetics undergoing lower
extremity bypass
Fuyuki Hirashima, MD,a Reshma B. Patel, MD,a Julie E. Adams, MD,b Daniel J. Bertges, MD,b
Peter W. Callas, PhD,c Georg Steinthorsson, MD,b Janet McSorley, APRN,b and
Andrew C. Stanley, MD,b Burlington, Vt
Objective: Strict glucose control in patients undergoing coronary bypass grafting has been shown to decrease infectious
complications, arrhythmias, and mortality. Our objective was to determine if strict glucose control reduced morbidity
after lower extremity bypass (LEB).
Methods:A prospective pilot study at a single institution within the Vascular Study Group of New England was conducted
from January 2009 to December 2010. Patients with diabetes and without undergoing LEB were placed on an
intravenous (IV) insulin infusion for 3 days after surgery with titration of blood glucose from 80 to 150 mg/dL. The IV
insulin study group (n  104) was compared to a historic control group (n  189) that received standard insulin
treatment from the preceding 3 years. The Fisher exact test, t-tests, Wilcoxon rank-sum tests, 2, and logistic regression
analyses were used to compare in-hospital morbidity. Stratified analyses were conducted to determine if findings differed
based on the presence or absence of diabetes.
Results: There was no difference in postoperative complications between the two groups with regard to graft infection,
myocardial infarction, dysrhythmia, primary patency at discharge, or mortality. Patients in the IV insulin group had
significantly fewer in-hospital wound infections (4% vs 11%; odds ratio [OR], 0.32; 95% confidence interval [CI],
0.11-0.96; P  .047). This association strengthened after adjusting for potentially confounding baseline differences in
gender, body mass index, and smoking status (adjusted OR, 0.22; 95% CI, 0.05-0.84; P  .03). When stratified by
presence of diabetes, wound infections were decreased in the IV insulin group (0/44 [0%] vs 9/90 [10%]; P  .03). In
patients without diabetes treated with IV insulin, there was no significant difference in wound infections (7% vs 12%;
P  .42).
Conclusions: Strict glucose control with a postoperative insulin infusion protocol significantly decreased the incidence of
postoperative in-hospital wound infection in the diabetic population. These previously unreported findings from this
single-institution prospective study warrant further investigation. (J Vasc Surg 2012;56:396-402.)
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oRecent literature has demonstrated the effectiveness of
glucose control protocols in reducing complications in
both coronary artery bypass grafting (CABG) and complex
patients in the intensive care unit. Protocols vary, but, in
general, use frequent blood glucosemonitoring and the use
of intravenous (IV) insulin to better control serum glucose.
In particular, reductions in mortality after CABG, intensive
care unit mortality, and infectious complications were ob-
served when these measures were instituted.1-3 Other stud-
ies have documented reductions in postoperative cardiac
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396omplications with these protocols in place.4 Some studies
ave reported complications related to the use of these
rotocols such as strokes, hypoglycemic events, and heart
lock requiring a pacemaker, leaving the potential risks and
enefits of strict glucose control still under debate.5,6 The-
retically, better glucose management should reduce com-
lications. A number of hypotheses have been postulated
egarding the mechanisms by which diabetes exerts its
egative effects on vascular physiology. Diabetes has been
orrelated with altered macrophage and neutrophil func-
ion,7,8 endothelial dysfunction,9 decrease in nitric oxide
ynthesis,10 and increase in the production of the vasocon-
trictor endothelin-1.11 Wound healing is compromised
ue to the microvascular effects of diabetes and alterations
n inflammatory response.12 It follows that by using a more
ggressive approach toward glucose normalization in the
ostoperative patient, some of the pathologic side effects of
he diabetic state, particularly wound and cardiac compli-
ations, should be avoidable. National attention on
ospital-acquired infections has been the basis for studies
hat document various risk factors for infection.13 Appro-
riate skin preparations, administration of antibiotics, type
f surgery, indications for surgery (treatment of infection),
nd surgical technique all play a role in expected rates of
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Volume 56, Number 2 Hirashima et al 397infection complications.14,15 The risk and avoidance of
infection is clearly multifactorial and complex.
Patients undergoing lower extremity bypass (LEB) sur-
gery are particularly at risk for postoperative cardiac com-
plications as well as wound and graft complications. Recent
center interval reports from the Vascular Study Group of
New England (VSGNE) database found wound complica-
tion rates at our center and other centers in New England
to be in the 10% to 12% range and the risk of cardiac
complications (arrhythmias, myocardial infarctions, and
congestive heart failure) to be in the range of 10% as
well.16,17 We conducted a single-center, nonrandomized,
prospective, pilot study within the VSGNE to examine the
effect of an IV insulin protocol on all patients undergoing
LEB. It was our hypothesis that by instituting this protocol
we could reduce complication rates in patients undergoing
LEB.
METHODS
Patients and databases. We used prospectively col-
lected data from the VSGNE, a regional cooperative group
dedicated to quality assessment and improvement in vascu-
lar surgery.18 The VSGNE quality vehicle was used at a
single institution to measure a change in clinical practice.
All patients undergoing LEB in our institution after Janu-
ary 2009 were treated with an IV insulin protocol. All
patient information was entered prospectively into the
VSGNE database and was later retrospectively queried and
compared to a historic control population. The historic
control population was comprised of all patients treated
with LEB at our institution from 2006 to 2008 before the
start of our pilot study.
Consecutive patients undergoing elective, urgent, or
emergent open infrainguinal LEB for occlusive or aneurys-
mal disease were included. Both diabetics and nondiabetics
were placed on standard insulin therapy before January
2009 and on intensive IV insulin treatment after that time
period. Indications for LEB included both claudication and
critical limb ischemia. A number of conduit types were
used, including vein, prosthetic, or composite grafts. Vein
harvests were performed as open procedures. Patients with
previous percutaneous transluminal angioplasty and/or
stents were included in the study. Supra-inguinal revascu-
larizations, extra-anatomic bypasses, and revascularizations
for trauma were excluded from analysis. Hospital protocol
dictates that preoperative preparation includes skin clipping
with no razors and skin preparation. Skin preparations
differed according to surgeon preference or as an allergy-
directed scrub. First-generation cephalosporin was given 1
hour before skin incision.
The institutional review board at the University of
Vermont reviewed the VSGNE program run by the Vascu-
lar Surgery Department and found it to fit under the
oversight of the James M. Jeffords Institute for Quality and
Operational Effectiveness at Fletcher Allen Health Care.
The use of IV insulin represents a practice change that we
have reviewed periodically via the VSGNE vehicle. cContinuous IV insulin protocol. Patients who were
laced on the IV insulin protocol received continuous IV
nsulin immediately postoperatively and continued for 72
ours (Appendix I, online only). The insulin infusion was
nitiated when the finger stick blood glucose (FSBG)
eached120 mg/dL, with a target titration goal between
0 and 150 mg/dL. If the FSBG was within this target
ange, the FSBG was initially checked every hour. After 6
ours of glucoses within this range, the monitoring was
engthened to every 2 hours. If the first postoperative FSBG
as 120 mg/dL, the glucose level was checked every 2
ours. If the initiation goal of 120 mg/dL was not
eached after 6 hours, the patient was switched to standard
nsulin coverage with FSBG levels obtained four times daily
efore meals and at bedtime.
To prevent hypoglycemia, the infusion was decreased
y 50% if the glucose level decreased below 80 mg/dL and
eld if the level dropped below 66 mg/dL with the addi-
ion of 12.5 g of D50 IV push or 15 g of oral carbohydrates.
f glucose levels dropped to 66 mg/dL, an FSBG was
echecked every 30 minutes. If the glucose level was be-
ween 66 and 79 mg/dL, an FSBG was checked every
our.
During periods of hyperglycemia, the insulin drip was
djusted so that the infusion was increased by 1 unit/hour
nce the glucose level reached 150 mg/dL, and it was
ncreased by 2 units/hour if 250 mg/dL, to a maximum
f 20 units/hour. When glucose levels were between 151
nd 499, FSBG was checked every 2 hours. If the glucose
evel increased to 500 mg/dL, the FSBG was rechecked
n 1 hour.
Standard insulin protocol. Diabetic and nondiabetic
istoric controls who underwent LEB from 2006 to 2008
ere placed on a standard insulin protocol. Standard treat-
ent can be defined as best medical therapy for the pa-
ient’s comorbidities. Postoperatively, patients in the his-
oric control group resumed their normal preoperative
ome regimen of antidiabetic medications (if they had been
n medications). If during the postoperative period they
ecame hyperglycemic and met parameters for the institu-
ion of insulin, they were placed on a supplemental insulin
spart sliding scale adjusted based on their nutritional sta-
us, blood glucose level, age, weight, and serum creatinine
Appendix II, online only). If the patient was not receiving
utritional intake by mouth, FSBG checks were imple-
ented every 6 hours. Once the patient was tolerating
utritional intake, FSBG checks were performed four times
aily before meals and at bedtime. If the patient had an
stablished home insulin regimen, they were restarted on
heir normal doses once they resumed eating in addition to
he insulin aspart sliding scale. Hypoglycemia prevention
onsisted of a 12.5-gD50 IV push if the FSBG decreased to
66 mg/dL.
Outcome measures. The primary outcome measures
ere in-hospital wound infection after LEB. According to
he VSGNE database, a wound infection is defined as the
nitiation of antibiotic treatment or positive culture. Clini-
al suspicion based on physical examination findings in-
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August 2012398 Hirashima et alcluded, but were not limited to, presence of erythema,
fever, or drainage from the wound site. Graft infection
according to the VSGNE is cited if antibiotics were initiated
or with documentation of exposed graft or graft infection in
the medical records. Secondary outcomes measured in-
cluded blood transfusion requirement, myocardial infarc-
tion, new dysrhythmia, congestive heart failure, respiratory
complication, amputation, length of stay, discharge ankle-
brachial and toe-brachial index, palpable graft pulse, palpa-
ble distal pulse, increase in ankle-brachial index0.15, and
duplex imaging. Return to the operating room for bleed-
ing, thrombosis, infection, or revision was also recorded.
Statistics. Baseline patient characteristics and out-
come measures were evaluated using the Fisher exact test
and 2 analysis for categorical data, two-sample t-test for
continuous variables that were normally distributed, and
Wilcoxon rank-sum test for non-normal continuous vari-
ables. Logistic regression analysis was used to adjust for
potential confounders such as body mass index (BMI),
gender, and smoking status. Stratified analyses were further
completed to look for differences that could be explained
by the presence or absence of diabetes. All statistical tests
were two-tailed and deemed significant if P  .05.
RESULTS
One hundred eighty-nine historic controls that under-
went LEB and were placed on standard insulin therapy
were evaluated. One hundred nineteen study patients were
placed on postoperative IV insulin during the time period
and were eligible for the study. Of the 119 patients in the
IV insulin group, 15 (13%) were excluded due to surgeon
preference (n  2), incomplete data (n  10), and lack of
protocol adherence (n  3), resulting in a total of 104
patients in the IV insulin study group.
Total patient population with lower extremity
bypass. There were no baseline differences between the
two groups with regard to preoperative characteristics,
except patients in the historic control group had a higher
BMI and an increased rate of prior and current smoking
compared to the IV insulin group (P .005 and .001), and
patients in the IV insulin group were more likely to be on a
preoperative statin and aspirin (P  .004 and P  .02;
Table). In the IV insulin group, five patients (5%) had their
diabetes controlled preoperatively with diet, 14 (13%) with
oral medications, and 25 (24%) with insulin. Within the
historic control group, 15 patients (8%) had their diabetes
controlled with diet, 32 (17%) with oral medications, and
43 (23%) with insulin. There was no significant difference
between the two groups (P  .63). There were no differ-
ences in the indication for surgery, graft type, or timing of
the operation.
A total of 21 patients in the historic control group and
four patients in the IV insulin group developed postopera-
tive wound infections. Out of the patients who developed
postoperative wound infections, six of 21 (30%) in the
historic control group and one of four (25%) in the IV
insulin group had preoperative wound infections (P 
1.00). Patients in the IV insulin group had significantly tewer wound infections compared with patients in the
istoric control group (4% vs 11%; odds ratio [OR], 0.32;
5% confidence interval [CI], 0.11-0.96; P  .047). The
ssociation remained significant in multivariate analyses
djusting for BMI, gender, and smoking status (OR, 0.22;
5% CI, 0.05-0.84; P  .03). Adjusting for statin use,
spirin use, and prosthetic vs vein graft did not change the
elationship between IV insulin use and postoperative
ound infection. The 15 patients excluded whowere on IV
nsulin and the 104 patients included who were on IV
nsulin were compared on 91 variables. The only significant
ifferences were that the 15 excluded patients were less
ikely to be diabetic (93% nondiabetic compared to 58%
ondiabetic for the 104 included; P  .02), more likely to
ave had a previous left leg bypass (53% vs 13% for the 104
ncluded; P .001), and lower BMI (mean of 24.7 vs 27.3
or the 104 included; P  .04). When those 15 patients
ere included in the analysis, the relationship between IV
nsulin use and wound infection was slightly stronger than
hen they were excluded (4% of IV insulin vs 11% in the
istoric control group; P  .036). Therefore, their exclu-
ion does not affect the observed IV insulin vs wound
nfection relationship. Patients in the IV insulin group had
decreased length of stay of 5.9 days compared to 6.5 days
or patients in the historic control group, however, the
esults were nonsignificant (P  .86).
Patients with postoperative wound infections had a
ignificantly longer length of stay (10.7 vs 5.9 days; P 
001). Patients with postoperative wound infections in the
V insulin group showed a trend toward an increased
ength of stay compared to those without wound infections
8.0 vs 5.8 days), however, this difference was only margin-
lly significant (P  .05). Patients in the historic control
roup with postoperative wound infections had an in-
reasedmean length of stay of 11.2 days compared with 5.9
ays for patients without wound infections (P  .003;
ig 1).
There were no differences in the rates of postoperative
raft infections, transfusions, myocardial infarctions, dys-
hythmias, congestive heart failure, or respiratory compli-
ations (Fig 2). One patient in the historic control group
eveloped a wound infection after blood transfusion. There
as no association between return to the operating room
or bleeding or thrombosis and the incidence of postoper-
tive wound infection (8% vs 9%; P 1.00). Hypoglycemia
glucose60 mg/dL) occurred in 19% (20/104; 95% CI,
.12-0.28) of patients on the insulin infusion without any
linically evident complications.
Diabetic population. Patients with diabetes in the IV
nsulin group had significantly less wound infections than
atients without diabetes in the historic control group (Fig
). None of the patients with diabetes in the IV insulin
roup developed postoperative wound infections com-
ared with 10% of patients with diabetes in the historic
ontrol group (P  .03). There was also a trend toward a
ecreased length of stay among patients with diabetes in
he IV insulin group compared to patients with diabetes in
he historic control group (6.8 vs 8.6 days; P  .26).
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with IV insulin, there were less wound infections compared
to those in the historic control group, however, the differ-
ence was not statistically significant (7% vs 12%; P  .42).
There was no difference in the length of stay for nondia-
Table. Patient characteristics
IV insulin
No. %
Gender
Male 83 81
Age
Mean (SD) 64.3 9.70
BMI
Mean (SD) 27.3 4.50
Smoking
Never 7 7
Prior 48 46
Current 49 47
HTN
Yes 86 83
Diabetes
None 60 58
Diet 5 5
Oral medications 14 13
IV insulin 25 24
CABG/PTCA
None 73 70
5 years 20 19
5 years 11 11
CHF
Yes 2 2
COPD
No 87 84
Not treated 9 9
On medications 7 7
Dialysis
No 100 96
Dialysis 3 3
Transplant 1 1
Pre-op ASA
Yes 97 95
Pre-op Plavix
Yes 2 2
Pre-op statin
Yes 82 81
Indication
Asymptomatic 11 11
Claudication 34 33
Rest pain 30 29
Tissue loss 26 25
Acute ischemia 3 3
Not treated 0 0
Graft
Vein 78 75
Prosthetic 26 25
Urgency
Elective 95 91
Urgent 8 8
Emergent 1 1
ASA,Acetylsalicylic acid (aspirin); BMI, bodymass index;CABG, coronary ar
disease; HTN, hypertension; IV, intravenous; PTCA, percutaneous translumbetics on IV insulin (5.3 vs 4.6 days; P  .27). tISCUSSION
Blood glucose levels are elevated postoperatively sec-
ndary to stress-induced production of catecholamines
licited by surgery. Although hyperglycemia and diabetes
re oftentimes indivisibly linked, it is unclear whether it is
Historic control
No. % P value
140 74 .25
65.2 11.60 .5
29.2 6.10 .005
21 11 .001
121 64
47 25
160 85 .74
99 52 .63
15 8
32 17
43 23
134 71 .89
38 20
17 9
9 5 .34
162 86 .35
9 5
17 9
183 97 .87
4 2
2 1
162 86 .02
8 4 .5
122 65 .004
20 11 .27
40 21
54 29
64 34
8 4
2 1
158 84 .09
31 16
164 87 .37
18 10
7 4
ypass;CHF, congestive heart failure;COPD, chronic obstructive pulmonary
oronary angioplasty.he diabetic state or whether hyperglycemia in and of itself
e
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glycemia is an independent risk factor for wound infections
among cardiothoracic patients with and without diabetes
Fig 3. Wound infections among diabetic and no
Fig 1. Length of
Fig 2. Postoperative complications.CHF,Congestive h
myocardial infarction.with a direct correlation between the degree of glucose Ilevation and risk of infection.2,19,20 Our study did not find
statistical difference in the rate of wound infections
mong diabetic compared to nondiabetic patients receiving
etic patients based on therapy. IV, Intravenous.
IV, Intravenous.
ilure; IV, intravenous; LEB, lower extremity bypass;MI,eart faV insulin, and it is unclear if strict perioperative glycemic
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Volume 56, Number 2 Hirashima et al 401control is as beneficial in the nondiabetic population as it is
for the diabetic population in the face of surgically induced
hyperglycemia.
The outcomes of tight glycemic control and incidence
of wound infections are not well documented in vascular
surgery patients. A retrospective study by Ramos et al21
examining diabetic and nondiabetic patients undergoing
general and vascular surgery found that postoperative hy-
perglycemia increased the risk of postoperative infection
(pneumonia, urinary tract infections, wound infections,
and sepsis) by 30% with every 40 mg/dL increase from
normoglycemia. Our study revealed that patients undergo-
ing LEB with strict postoperative glycemic control had
significantly decreased wound infections. Furthermore, pa-
tients with diabetes receiving IV insulin had significantly
less wound infections compared to patients with diabetes in
the historic control group treated with standard insulin
therapy.
The application of intensive insulin therapy is accom-
panied by the potential for hypoglycemia-related events.
The NICE-SUGAR trial revealed that strict glycemic con-
trol (81-108 mg/dL) increased mortality among critically
ill patients.22 Subramaniam et al4 found that episodes of
hypoglycemia were 3.1% vs 4.1% among vascular surgery
patients on intensive insulin therapy compared to standard
therapy, respectively, with no clinically evident symptoms.
Nineteen percent (20/104) of our patients in the IV insu-
lin protocol had hypoglycemia (glucose60mg/dL), with
no episodes of severe hypoglycemia (glucose40mg/dL).
Neither mild nor severe clinical manifestations of hypogly-
cemia were experienced among our study subjects. Our
small sample size is a limitation in determining the extent of
the potential consequences of hypoglycemia. This study
demonstrates the benefits of decreased wound infections in
the subgroup of patients with diabetes placed on IV insulin,
however, it is indeterminate if strict glucose control in
nondiabetics is as advantageous.
Despite the risk of hypoglycemic events, tight glycemic
control may improve patient outcomes by reducing length
of stay. Studies have demonstrated a correlation between
hyperglycemia and increased length of hospitalization.6,21
Within our population, patients with postoperative wound
infections had a significantly longer length of hospital stay
compared to patients without a postoperative wound infec-
tion. Patients with diabetes on IV insulin showed a trend
toward a shorter length of stay compared to patients with
diabetes in the IV insulin group suggesting an additional
benefit to the use of tight glycemic control within the
postoperative period.
This study had several limitations, including its small
sample size and observational design. Although the data
were collected prospectively, historic controls were used for
comparison purposes. However, there were few differences
in patient characteristics between the two groups, and
adjusting for these differences did not change the findings.
We estimate a trial of over 1800 patients is needed to detect
a 50% reduction of in-hospital wound infections at 80%
power. This pilot study serves as proof of concept to justifyrandomized controlled trial of glucose control after LEB.
e likely underestimated the rate of wound infections
ecause a significant number of wound infections present
fter discharge. Furthermore, the complications associated
ith hypoglycemic events may not have been diagnosed at
he time or documented appropriately.
ONCLUSIONS
Strict glycemic control with a postoperative insulin
nfusion protocol significantly decreased the incidence of
n-hospital postoperative wound infection in patients un-
ergoing LEB. In subpopulation analysis, patients with
iabetes benefited from the use of this protocol more than
ther populations studied. It is our belief that the use of an
V insulin protocol can help reduce complications in the
iabetic population.
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A. Physician notification:
● Automatic assessment and action - critical laboratory
values are finger-stick blood glucose (FSBG) 50
mg/dL or 500 mg/dL. FSBG values 500
mg/dL require serum blood glucose (BG) confirma-
tion. If FSBG 50 mL/dL, do not delay treatment.
—If eating, FSBG checked four times daily before
meals and at bedtime.
—If NPO, glucose check Q6.
—If FSBG66 mg/dL and patient cannot swallow or
is NPO.
—Administer 25 mL D50 intravenous (IV) push stat
and call LP. Recheck FSBG in 15 minutes and 60
minutes for response.
—If FSBG is66mg/dL in the AM, treat as above and
recheck FSBG at 0200 for 2 nights.
—If FSBG is 66 mg/dL  2 in the last 6 hours treat
as above and call LP.
B. FSBG checks
C. Hypoglycemia prevention
D. Bedtime FSBG:
Œ If bedtime FSBG 250 mg/dL, 5 units of supple-
mental insulin will be given and FSBG will be re-
checked at midnight.
E. Supplemental insulin aspart protocol if patient is NPO
24 hours:
Critical values are FSBG 50 mg/dL or 500
mg/dL.
Dosing regimen for SCr 3.5, age 80
FSBG Units of insulin aspart
66-140 0
141-180 0
181-210 1
211-250 2
251-299 3
299 5
Dosing regimen weight between 50 and 75 kg
FSBG Units of insulin aspart
66-140 0
141-180 1
181-210 2
211-250 4
251-299 6
299 9
Dosing regimen weight between 76 and 100 kg
FSBG Units of insulin aspart
66-140 0
141-180 2
181-210 3
211-250 5
251-299 7ppendix II (online only). Continued.
SBG Units of insulin aspart
299 11
Dosing regimen weight between 101 and 125 kg
SBG Units of insulin aspart
6-140 0
41-180 3
81-210 4
11-250 6
51-299 8
299 12
osing regimen weight 125 kg
SBG Units of insulin aspart
6-140 0
41-180 4
81-210 5
11-250 7
51-299 9
299 13
UPPLEMENTAL INSULIN ASPART WHEN PA-
IENT IS EATING
osing regimen for SCr 3.5, age 80
SBG Units of insulin aspart
6-140 0
41-180 0
81-210 1
11-250 2
51-299 3
299 5
osing regimen weight between 50 and 75 kg
SBG Units of insulin aspart
6-140 0
41-180 1
81-210 2
11-250 4
51-299 6
299 9
osing regimen weight between 76 and 100 kg
SBG Units of insulin aspart
6-140 0
41-180 2
81-210 3
11-250 5
51-299 7
299 11
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Dosing regimen weight between 101 and 125 kg
FSBG Units of insulin aspart
66-140 0
141-180 3
181-210 4
211-250 6
251-299 8
299 12ppendix II (online only). Continued.
osing regimen weight 125 kg
SBG Units of insulin aspart
6-140 0
41-180 4
81-210 5
11-250 7
51-299 9
299 13
